Modeling the pharmaceutical pipeline with revenue reducitions of 10% (IMAGE)
Caption
Three scenarios for reducing R&D expense in response to a 10% decrease in pharmaceutical revenue. The model assumes different levels of cost reduction by companies of different size and that cost reductions will be achieved by reduction of spending on phased clinical trials. The three scenarios posit differential allocation of cost reductions between phase 1, phase 2, or phase 3 trials.
Credit
West Health and Bentley University
Usage Restrictions
No
License
Original content